About HDL Therapeutics
HDL Therapeutics is a company based in Short Hills (United States) founded in 2010.. HDL Therapeutics has raised $17.79 million across 6 funding rounds. HDL Therapeutics offers products and services including PDS-2 System. HDL Therapeutics operates in a competitive market with competitors including Silk Road Medical, Supira Medical, Lifetech Scientific Corporation, Shanghai Baixin'an Biotechnology and AVS Pulse, among others.
- Headquarter Short Hills, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hdl Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$17.79 M (USD)
in 6 rounds
-
Latest Funding Round
$1.27 M (USD), Series B
Jul 07, 2023
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HDL Therapeutics
HDL Therapeutics offers a comprehensive portfolio of products and services, including PDS-2 System. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
FDA-approved therapy to regress plaques using HDL cholesterol
Unlock access to complete
Unlock access to complete
Funding Insights of HDL Therapeutics
HDL Therapeutics has successfully raised a total of $17.79M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $1.27 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series B — $1.3M
-
First Round
First Round
(13 Feb 2013)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2023 | Amount | Series B - HDL Therapeutics | Valuation |
investors |
|
| Mar, 2021 | Amount | Series B - HDL Therapeutics | Valuation |
investors |
|
| Oct, 2019 | Amount | Series B - HDL Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by HDL Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - HDL Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hdl Therapeutics Comparisons
Competitors of HDL Therapeutics
HDL Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Silk Road Medical, Supira Medical, Lifetech Scientific Corporation, Shanghai Baixin'an Biotechnology and AVS Pulse, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of neuroprotection devices for carotid artery disease
|
|
| domain | founded_year | HQ Location |
Developer of ventricular assist devices for coronary intervention and cardiogenic shock
|
|
| domain | founded_year | HQ Location |
Interventional devices for cardiovascular and vascular diseases are developed.
|
|
| domain | founded_year | HQ Location |
A bioabsorbable coronary rapamycin-eluting stent system is developed using PLLA.
|
|
| domain | founded_year | HQ Location |
Pulsatile intravascular lithotripsy is developed for calcified arterial disease treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Hdl Therapeutics
Frequently Asked Questions about HDL Therapeutics
When was HDL Therapeutics founded?
HDL Therapeutics was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Where is HDL Therapeutics located?
HDL Therapeutics is headquartered in Short Hills, United States. It is registered at Short Hills, New Jersey, United States.
Is HDL Therapeutics a funded company?
HDL Therapeutics is a funded company, having raised a total of $17.79M across 6 funding rounds to date. The company's 1st funding round was a Series B of $3M, raised on Feb 13, 2013.
What does HDL Therapeutics do?
HDL Therapeutics was founded in 2010 and is based in Short Hills, United States. Focus is placed on the biotechnology sector, where the PDS-2 System is developed as a therapeutic device. Patient plasma is utilized to generate natural pre-β HDL, by which plaques are reduced in coronary arteries. Cardiovascular disorder risks are thereby lowered through these operations.
Who are the top competitors of HDL Therapeutics?
HDL Therapeutics's top competitors include Silk Road Medical, Lifetech Scientific Corporation and InterShunt Technologies.
What products or services does HDL Therapeutics offer?
HDL Therapeutics offers PDS-2 System.